1
|
Navinés R, Oriolo G, Mora M, Cavero M, Gómez-Gil E, Martin-Santos R. Less basal thyrotropin levels predict antidepressant response in patients with major depression. Eur Psychiatry 2022. [PMCID: PMC9565975 DOI: 10.1192/j.eurpsy.2022.662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Introduction The close association among thyroid metabolism, mood disorders and behavior has long been known. The role of basal thyroid axis in antidepressant treatment response is less known. Objectives The aim of the present study was to study the association of basal serum thyrotropin (TSH) levels, with antidepressant treatment response in major depressive disorder. Methods Thirty-one depressed adult outpatients were included. Major depressive episode was diagnosed through the MINI (DSM-IV-TR) interview. Clinical symptomatology and blood samples were assessed at baseline, and at 4-
and 8-weeks of either escitalopram or sertraline. Treatment response was defined by an improvement ≥50% in MADRS scores at 4-, and 8-weeks. Basal TSH levels were included in a linear regression model as predictor of treatment response. Results Twenty-seven patients finished 8-weeks of treatment. Response to treatment was of 74% at 4-weeks, and 63% at 8-weeks of antidepressant treatment. Basal median TSH levels were between normal ranges (M+SD=1.85+1,02 mlU/L). Basal TSH levels not correlated with basal MADRS scores, but with higher MADRS scores at week-4 (r=0,415, p=0,031) and at week-8 (r=0,392, p=0,043). Moreover, less baseline TSH levels trend to be a significant good predictor for treatment response at 4-weeks (R2=.116, p=.083); and a good predictor at 8-weeks treatment (R2=.147, p=.049). Conclusions Baseline TSH levels even within the normal range may play a role in predicting antidepressant response. Disclosure No significant relationships.
Collapse
|
2
|
Cussotto S, Delgado I, Oriolo G, Kemper J, Begarie D, Dexpert S, Sauvant J, Leboyer M, Aouizerate B, Martin-Santos R, Schaefer M, Capuron L. Low omega-3 polyunsaturated fatty acids predict reduced response to standard antidepressants in patients with major depressive disorder. Depress Anxiety 2022; 39:407-418. [PMID: 35357051 DOI: 10.1002/da.23257] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/22/2021] [Revised: 02/07/2022] [Accepted: 03/17/2022] [Indexed: 11/07/2022] Open
Abstract
BACKGROUND Major depressive disorder (MDD) is characterized by a high rate of treatment resistance. Omega (ω)-3 polyunsaturated fatty acids (PUFAs) were shown to correlate with depressive phenotype both in rodents and in humans. However, few studies to date have investigated the role of PUFAs in antidepressant response. The primary aim of this study was to assess the link between baseline PUFA composition and changes in depressive symptoms as well as antidepressant response in a multicenter study of depressed patients. METHODS Sixty depressed adults who met criteria for MDD according to DSM-IV-TR were recruited. Neuropsychiatric evaluations occurred at baseline and after 4 and 8 weeks of treatment with standard antidepressants, including escitalopram (N = 45), sertraline (N = 13) and venlafaxine (N = 2). At study endpoint, patients were stratified into responders (R) or non-responders (NR) based on their MADRS (Montgomery-Åsberg Depression Rating Scale) score. Baseline PUFA levels were assessed and their association with clinical response was determined. RESULTS Lower ω-3 PUFA levels were associated to worse baseline symptomatology. Baseline levels of PUFAs were significantly different between R and NR, with R exhibiting lower docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and ω-3 index; and higher ω-6/ω-3 ratio than NR before the start of antidepressant treatment. DHA levels as well as the ω-3 index and ω-6/ω-3 ratio significantly predicted response to antidepressants at study endpoint. CONCLUSIONS These results show that baseline levels of PUFAs predict later response to standard antidepressants in depressed subjects. They suggest that PUFA intake and/or metabolism represent a novel modifiable tool for the management of unresponsive depressed patients.
Collapse
Affiliation(s)
- Sofia Cussotto
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| | - Inês Delgado
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| | - Giovanni Oriolo
- Department of Psychiatry and Psychology, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Jonas Kemper
- Department of Psychiatry, Psychotherapy, Psychosomatics, and Addiction Medicine, Evang. Kliniken Essen-Mitte, Essen, Germany
| | - Diane Begarie
- Departement de Biologie, École Normale Supérieure de Lyon, Université Claude Bernard Lyon I, Université de Lyon, Lyon, France
| | - Sandra Dexpert
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| | - Julie Sauvant
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| | - Marion Leboyer
- INSERM, U955, Translational Neuro-Psychiatry lab, Institut Mondor de Recherche Biomédicale, Créteil, France.,AP-HP, Département Universitaire d'Addictologie et Psychiatrie des Hôpitaux Henri Mondor University Hospital, Université Paris Est Créteil, Créteil, France
| | - Bruno Aouizerate
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France.,CH Charles Perrens, Pôle de Psychiatrie Générale et Universitaire, Centre de référence régional des pathologies anxieuses et dépressives, Bordeaux, France
| | - Rocío Martin-Santos
- Department of Psychiatry and Psychology, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - Martin Schaefer
- Department of Psychiatry, Psychotherapy, Psychosomatics, and Addiction Medicine, Evang. Kliniken Essen-Mitte, Essen, Germany.,Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Lucile Capuron
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| |
Collapse
|
3
|
Navinés R, Oriolo G, Horrillo I, Cavero M, Aouizerate B, Schaefer M, Capuron L, Meana JJ, Martin-Santos R. High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers. Int J Neuropsychopharmacol 2022; 25:468-478. [PMID: 35176771 PMCID: PMC9211008 DOI: 10.1093/ijnp/pyac016] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 01/31/2022] [Accepted: 02/17/2022] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD). METHODS We included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-Åsberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, C-reactive protein (CRP), and high-density lipoprotein cholesterol (HDL)-C levels. Treatment response was defined as ≥50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response. RESULTS Twenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R2 = 0.457, P = .001), while S100B was at week 8 (R2 = 0.239, P = .011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement. CONCLUSIONS Serum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers.
Collapse
Affiliation(s)
- Ricard Navinés
- Department of Psychiatry and Psychology, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Barcelona, Spain
| | - Giovanni Oriolo
- Department of Psychiatry and Psychology, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Barcelona, Spain,Hospital de día Córcega, Centre Psicoterapèutic Barcelona (CPB); and Department of Experimental and Health Sciences, Psychiatry Unit, Universitat Pompeu Fabra, Barcelona, Spain
| | - Igor Horrillo
- Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; CIBERSAM, Leioa, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain
| | - Myriam Cavero
- Department of Psychiatry and Psychology, Hospital Clinic, Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona; Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Barcelona, Spain
| | - Bruno Aouizerate
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France,CH Charles Perrens, Pole de Psychiatrie Générale et Universitaire, Centre de référence régional des pathologies anxieuses et de la dépression, Bordeaux, France
| | - Martin Schaefer
- Department of Psychiatry and Psychotherapy, Charité-Universitâtsmedizin Berlin, Campus Charité Mitte, Berlin, Germany,Department of Psychiatry, Psychotherapy, Psychosomatics and Addiction Medicine, Evang. Kliniken Es-sen-Mitte, Essen, Germany
| | - Lucile Capuron
- University of Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, Bordeaux, France
| | - J Javier Meana
- Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain; CIBERSAM, Leioa, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Bizkaia, Spain
| | - Rocio Martin-Santos
- Correspondence: Rocio Martin-Santos, MD, PhD, Senior Consultant, Department of Psychiatry and Psychology, Hospital Clinic, IDIBAPS, CIBERSAM; and Department of Medicine, Institute of Neuroscience, University of Barcelona, 08036-Barcelona, Spain ()
| |
Collapse
|
4
|
Bioque M, Parellada E, García-Rizo C, Amoretti S, Fortea A, Oriolo G, Palau P, Boix-Quintana E, Safont G, Bernardo M. Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study. Eur Psychiatry 2020; 63:e71. [PMID: 32669145 PMCID: PMC7443780 DOI: 10.1192/j.eurpsy.2020.72] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
Background: Around 30% of patients with schizophrenia are considered treatment resistant (TRS). Only around 40% of TRS patients respond to clozapine. Long acting injectable antipsychotics could be a useful augmentation strategy for nonresponders. Methods: We conducted a multicenter, observational, naturalistic, retrospective, 6-month mirror-image study to evaluate the efficacy and tolerability of clozapine and paliperidone palmitate association in 50 patients with TRS and other psychotic disorders. Clinical outcomes and side effects were systematically assessed. Results: Six months after starting the combined treatment, participants showed a significant relief of symptoms, decreasing the Brief Psychiatric Rating Scale total score from 18.32 ± 7.71 to 7.84 ± 5.16 (p < 0.001). The number of hospitalizations, the length of hospital stays and the number of visits to emergency services also decreased, while an increase of the functionality was observed (Personal and Social Performance total score increased from 46.06 ± 118.7 to 60.86 ± 18.68, p < 0.001). There was also a significant decrease in the number and severity of side effects with the combination therapy, decreasing the Udvalg for Kliniske Undersogelser total score from 10.76 ± 8.04 to 8.82 ± 6.63 (p = 0.004). Conclusions: This study provides the first evidence that combining clozapine with paliperidone palmitate in patients with TRS and other psychotic disorders could be effective and safe, suggesting further research with randomized controlled trials of augmentation strategies for clozapine nonresponder patients. Policy Significance Statement: Patients with psychotic disorders such as schizophrenia show a variable response to antipsychotic treatments. Around 30% of patients are considered treatment resistant, indicated by insufficient symptom control to at least two different drugs. In these resistant cases, clozapine should be indicated, as it has shown to be superior to other options. However, only 40% of patients respond to clozapine, being necessary to establish which treatments could best potentiate clozapine action. Combining clozapine with long acting injectable antipsychotics, and particularly paliperidone palmitate, could be a useful strategy. We conducted a multicenter study of 50 patients with treatment-resistant schizophrenia and other psychotic disorders comparing the efficacy and tolerability in the 6 month-period prior and after starting the clozapine and paliperidone palmitate association. Our study suggests that this combination could be effective and safer, laying the groundwork for future clinical trials with this combination.
Collapse
Affiliation(s)
- Miquel Bioque
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Madrid, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Eduard Parellada
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Madrid, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Clemente García-Rizo
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Madrid, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Sílvia Amoretti
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Madrid, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Adriana Fortea
- Child and Adolescent Psychiatry and Psychology Department, Institute of Neurosciences, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.,Fundació Clinic per a la Recerca Biomèdica (FCRB), Barcelona, Spain
| | - Giovanni Oriolo
- Psychiatry Department, Neuroscience Institute, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain.,Day Hospital, Centre Psicoteràpia Barcelona (CPB), Barcelona, Spain
| | - Pol Palau
- Psychiatry Department, Hospital General de Granollers, Granollers, Spain
| | | | - Gemma Safont
- Psychiatry Department, Hospital Universitari Mútua de Terrassa, Terrassa, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Miquel Bernardo
- Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.,Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Madrid, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| |
Collapse
|
5
|
Egmond E, Mariño Z, Navines R, Oriolo G, Pla A, Bartres C, Lens S, Forns X, Martin-Santos R. Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. Braz J Psychiatry 2020; 42:72-76. [PMID: 31314868 PMCID: PMC6986477 DOI: 10.1590/1516-4446-2018-0336] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Accepted: 04/18/2019] [Indexed: 01/19/2023]
Abstract
OBJECTIVE Depression has been associated with hepatitis C, as well as with its treatment with proinflammatory cytokines (i.e., interferon). The new direct-acting antiviral agents (DAAs) have minimal adverse effects and high potency, with a direct inhibitory effect on non-structural viral proteins. We studied the incidence and associated factors of depression in a real-life prospective cohort of chronic hepatitis C patients treated with the new DAAs. METHODS The sample was recruited from a cohort of 91 patients with hepatitis C, of both sexes, with advanced level of fibrosis and no HIV coinfection, consecutively enrolled during a 6-month period for DAA treatment; those euthymic at baseline (n=54) were selected. All were evaluated through the depression module of the Patient Health Questionnaire (PHQ-9-DSM-IV), at three time points: baseline, 4 weeks, and end-of-treatment. RESULTS The cumulative incidence (95%CI) of major depression and any depressive disorder during DAA treatment was 13% (6.4-24.4) and 46.3% (33.7-59.4), respectively. No differences were observed between those patients with and without cirrhosis or ribavirin treatment (p > 0.05). Risk factors for incident major depression during DAA treatment included family depression (relative risk 9.1 [1.62-51.1]), substance use disorder (11.0 [1.7-73.5]), and baseline PHQ-9 score (2.1 [1.1-3.1]). CONCLUSIONS The findings of this study highlight the importance of screening for new depression among patients receiving new DAAs, and identify potential associated risk factors.
Collapse
Affiliation(s)
- Elfi Egmond
- Servei de Psiquiatria i Psicologia, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
- Departament de Psicologia Clínica i de la Salut, Facultat de Psicologia, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Zoe Mariño
- Servei d’Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain
| | - Ricard Navines
- Servei de Psiquiatria i Psicologia, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
- Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain
| | - Giovanni Oriolo
- Servei de Psiquiatria i Psicologia, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
- Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain
| | - Anna Pla
- Servei d’Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain
| | - Concepció Bartres
- Servei d’Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain
| | - Sabela Lens
- Servei d’Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain
| | - Xavier Forns
- Servei d’Hepatologia, Hospital Clínic de Barcelona, IDIBAPS, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat de Barcelona, Barcelona, Spain
| | - Rocio Martin-Santos
- Servei de Psiquiatria i Psicologia, Hospital Clínic de Barcelona, Institut d’Investigacions Biomèdicas August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain
- Institut de Neurociències, Universitat de Barcelona, Barcelona, Spain
- Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Ribeirão Preto, Brazil
| |
Collapse
|
6
|
Oriolo G, Blanco-Hinojo L, Navines R, Mariño Z, Martín-Hernández D, Cavero M, Gimenez D, Caso J, Capuron L, Forns X, Pujol J, Sola R, Martin-Santos R. Association of chronic inflammation and perceived stress with abnormal functional connectivity in brain areas involved with interoception in hepatitis C patients. Brain Behav Immun 2019; 80:204-218. [PMID: 30872094 DOI: 10.1016/j.bbi.2019.03.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2018] [Revised: 02/06/2019] [Accepted: 03/09/2019] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Sickness behavioral changes elicited by inflammation may become prolonged and dysfunctional in patients with chronic disease, such as chronic hepatitis C (CHC). Neuroimaging studies show that the basal ganglia and insula are sensitive to systemic inflammation. AIM To elucidate the clinical and neurobiological aspects of prolonged illnesses in patients with CHC. METHODS Thirty-five CHC patients not treated with interferon-α or other antiviral therapy, and 30 control subjects matched for age and sex, were evaluated for perceived stress (perceived stress scale; PSS), depression (PHQ-9), fatigue and irritability through a visual analog scale (VAS), as well as serum levels of interleukin-6 (IL-6), prostaglandin E2 (PGE2) and oxidative stress markers. Functional MRI was performed, measuring resting-state functional connectivity using a region-of-interest (seed)-based approach focusing on the bilateral insula, subgenual anterior cingulate cortex and bilateral putamen. Between-group differences in functional connectivity patterns were assessed with two-sample t-tests, while the associations between symptoms, inflammatory markers and functional connectivity patterns were analyzed with multiple regression analyses. RESULTS CHC patients had higher PSS, PHQ-9 and VAS scores for fatigue and irritability, as well as increased IL-6 levels, PGE2 concentrations and antioxidant system activation compared to controls. PSS scores positively correlated with functional connectivity between the right anterior insula and right putamen, whereas PHQ-9 scores correlated with functional connectivity between most of the seeds and the right anterior insula. PGE2 (positively) and IL-6 (negatively) correlated with functional connectivity between the right anterior insula and right caudate nucleus and between the right ventral putamen and right putamen/globus pallidus. PGE2 and PSS scores accounted for 46% of the variance in functional connectivity between the anterior insula and putamen. CONCLUSIONS CHC patients exhibited increased perceived stress and depressive symptoms, which were associated with changes in inflammatory marker levels and in functional connectivity between the insula and putamen, areas involved in interoceptive integration, emotional awareness, and orientation of motivational state.
Collapse
Affiliation(s)
- Giovanni Oriolo
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigacion Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Medicine, Faculty of Medicine, and Institute of Neuroscience, University of Barcelona (UB), Barcelona, Spain
| | - Laura Blanco-Hinojo
- MRI Research Unit, Department of Radiology, Hospital del Mar, CIBERSAM, G21, Barcelona, Spain
| | - Ricard Navines
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigacion Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Medicine, Faculty of Medicine, and Institute of Neuroscience, University of Barcelona (UB), Barcelona, Spain
| | - Zoe Mariño
- Liver Unit, Hospital Clinic, IDIBAPS, Centro Investigacion Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain
| | - David Martín-Hernández
- Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, CIBERSAM, Imas12, IUINQ, Madrid, Spain
| | - Myriam Cavero
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigacion Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Medicine, Faculty of Medicine, and Institute of Neuroscience, University of Barcelona (UB), Barcelona, Spain
| | - Dolors Gimenez
- Liver Section, Hospital del Mar, Parc de Salut Mar, Grup de Recerca Hepatológica, FIMIM, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - Javier Caso
- Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense de Madrid, CIBERSAM, Imas12, IUINQ, Madrid, Spain
| | - Lucile Capuron
- INRA, Laboratory of Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, F-33076 Bordeaux, France; University of Bordeaux, Laboratory of Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, F-33076 Bordeaux, France
| | - Xavier Forns
- Liver Unit, Hospital Clinic, IDIBAPS, Centro Investigacion Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), University of Barcelona, Barcelona, Spain
| | - Jesus Pujol
- MRI Research Unit, Department of Radiology, Hospital del Mar, CIBERSAM, G21, Barcelona, Spain
| | - Ricard Sola
- Liver Section, Hospital del Mar, Parc de Salut Mar, Grup de Recerca Hepatológica, FIMIM, Universitat Autónoma de Barcelona, Barcelona, Spain
| | - Rocio Martin-Santos
- Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigacion Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain; Department of Medicine, Faculty of Medicine, and Institute of Neuroscience, University of Barcelona (UB), Barcelona, Spain.
| |
Collapse
|
7
|
Oriolo G, Huet L, Dexpert S, Beau C, Forestier D, Ledaguenel P, Magne E, Martin-Santos R, Capuron L. History of major depression is associated with neuropsychiatric symptoms but not systemic inflammation in a cross-sectional study in obese patients. Brain Behav Immun 2019; 76:215-222. [PMID: 30476563 DOI: 10.1016/j.bbi.2018.11.312] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/04/2018] [Revised: 10/05/2018] [Accepted: 11/22/2018] [Indexed: 11/30/2022] Open
Abstract
Obesity is a major public health burden associated with neuropsychiatric comorbidities leading to social and occupational impairment. Given the growing prevalence of both obesity and mental disorders worldwide, understanding the risk factors of obesity-related neuropsychiatric comorbidities is crucial to develop preventive strategies and individualized treatments. Recent findings suggest that adiposity-driven inflammation contributes to neuropsychiatric comorbidities in obesity. However, not all obese subjects afflicted with chronic inflammation develop neuropsychiatric symptoms, suggesting additional risk factors. The aim of this study was to investigate the impact of personal history of major depressive disorder (MDD) on obesity-related inflammation and neuropsychiatric symptoms, and their relationship. A case-control study was conducted comparing 66 obese patients (body mass index > 35 kg/m2) and 22 healthy non-obese participants, free of any current neuropsychiatric diseases including MDD. Neuropsychiatric symptoms were assessed using the Neurotoxicity Rating Scale (NRS). Sociodemographic and clinical variables were gathered and blood was collected for the measurement of serum levels of high-sensitivity C-reactive protein (hs-CRP). Multiple regression analyses were performed to assess the contribution of obesity and personal history of MDD to clinical outcomes and inflammatory status in study participants. Hs-CRP levels as well as NRS scores were significantly increased in the obese group. Overall, personal history of depression accounted for increased NRS scores but no significant association was found with inflammatory status. In addition, history of depression did not significantly modulate the relationship of obesity-related inflammation with NRS scores. Interestingly, obese individuals with history of recurrent MDD (n = 13) exhibited higher scores in the cognitive and sickness symptoms dimensions of the NRS compared to obese subjects with history of one depressive episode only. Findings indicate that history of depression contributes to neuropsychiatric symptoms, but not to systemic inflammation, in obese subjects free of current depressive episode. These results provide relevant information on the risk factors that may help identify obese subjects with increased risk of neuropsychiatric comorbidity.
Collapse
Affiliation(s)
- Giovanni Oriolo
- INRA, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France; University of Bordeaux, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France; Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, Spain; Department of Medicine, University of Barcelona, Barcelona, Catalonia, Spain
| | - Lison Huet
- INRA, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France; University of Bordeaux, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France
| | - Sandra Dexpert
- INRA, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France; University of Bordeaux, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France
| | - Cédric Beau
- Service de Chirurgie Digestive et Pariétale, Clinique Tivoli, 33000 Bordeaux, France; Clinique Jean Villar, 33520 Bruges, France
| | - Damien Forestier
- Service de Chirurgie Digestive et Pariétale, Clinique Tivoli, 33000 Bordeaux, France; Clinique Jean Villar, 33520 Bruges, France
| | - Patrick Ledaguenel
- Service de Chirurgie Digestive et Pariétale, Clinique Tivoli, 33000 Bordeaux, France; Clinique Jean Villar, 33520 Bruges, France
| | - Eric Magne
- Service de Chirurgie Digestive et Pariétale, Clinique Tivoli, 33000 Bordeaux, France; Clinique Jean Villar, 33520 Bruges, France
| | - Rocío Martin-Santos
- Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, Spain; Department of Medicine, University of Barcelona, Barcelona, Catalonia, Spain
| | - Lucile Capuron
- INRA, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France; University of Bordeaux, Nutrition and Integrative Neurobiology (NutriNeuro), UMR 1286, 33076 Bordeaux, France.
| |
Collapse
|
8
|
Fortea A, Ilzarbe D, Espinosa L, Solerdelcoll M, de Castro C, Oriolo G, Sugranyes G, Baeza I. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study. J Child Adolesc Psychopharmacol 2018; 28:252-257. [PMID: 29381388 DOI: 10.1089/cap.2017.0096] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in children and adolescents. Thus, we systematically describe the off-label use of SG-LAIAs in clinical practice in adolescent inpatients. METHODS All individuals admitted to our Children and Adolescent Inpatient Psychiatry Unit receiving treatment with SG-LAIAs between January 2013 and June 2016 were reviewed. A retrospective analysis of medical records was conducted. Clinical diagnoses were established using DSM-5 criteria. RESULTS Thirty individuals (53.3% female) out of a total of 1,148 admitted patients (2.6%) were identified. The mean age was 16.3 (SD = 1.3; range: 12.5-17.9).The main diagnoses were psychosis (70%) and disruptive behavior disorders (DBDs) (30%), although comorbidity was frequent (96.6%), especially drug use (55.2%, mostly cannabis). SG-LAIAs used were aripiprazole (40%), risperidone (36.7%), and paliperidone palmitate (23.3%), and the main reasons were a history of low compliance (90%) and/or poor insight (73.3%). A mean improvement of 31.7 (SD = 8.7) between admission and discharge was registered in the Children's Global Assessment Scale (CGAS); no differences were observed between different SG-LAIAs. Although they were generally well tolerated, 23.3% of patients reported mild short-term side effects, which were more frequent with risperidone than with aripiprazole (p = .014). CONCLUSIONS Our clinical experience suggests that SG-LAIAs may be a safe treatment option during adolescence in inpatients with psychotic disorders, as well as with DBD. No differences were found in CGAS improvement scores between the three SGA-LAIAs used, although patients on risperidone reported more side effects than those on aripiprazole. Further research is needed so as to evaluate safety and effectiveness of SG-LAIAs in this population.
Collapse
Affiliation(s)
- Adriana Fortea
- 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic de Barcelona , Barcelona, Spain
| | - Daniel Ilzarbe
- 2 Department of Child and Adolescent Psychiatry, Institute of Psychiatry, King's College of London , London, United Kingdom
| | - Laura Espinosa
- 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic de Barcelona , Barcelona, Spain
| | - Mireia Solerdelcoll
- 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic de Barcelona , Barcelona, Spain
| | - Clara de Castro
- 3 Centro de Salud Mental Infanto-Juvenil, Hospital Sant Joan de Déu , Cornellá de Llobregat, Barcelona, Spain
| | - Giovanni Oriolo
- 1 Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic de Barcelona , Barcelona, Spain
| | - Gisela Sugranyes
- 4 Department of Child and Adolescent Psychiatry, Institute of Neuroscience, Hospital Clínic de Barcelona , Barcelona, Spain .,5 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (CERCA-IDIBAPS) , Barcelona, Spain .,6 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) , Barcelona, Spain
| | - Inmaculada Baeza
- 4 Department of Child and Adolescent Psychiatry, Institute of Neuroscience, Hospital Clínic de Barcelona , Barcelona, Spain .,5 Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (CERCA-IDIBAPS) , Barcelona, Spain .,6 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) , Barcelona, Spain
| |
Collapse
|
9
|
Oriolo G, Egmond E, Mariño Z, Cavero M, Navines R, Zamarrenho L, Solà R, Pujol J, Bargallo N, Forns X, Martin-Santos R. Systematic review with meta-analysis: neuroimaging in hepatitis C chronic infection. Aliment Pharmacol Ther 2018. [PMID: 29536563 DOI: 10.1111/apt.14594] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND Chronic hepatitis C is considered a systemic disease because of extra-hepatic manifestations. Neuroimaging has been employed in hepatitis C virus-infected patients to find in vivo evidence of central nervous system alterations. AIMS Systematic review and meta-analysis of neuroimaging research in chronic hepatitis C treatment naive patients, or patients previously treated without sustained viral response, to study structural and functional brain impact of hepatitis C. METHODS Using PRISMA guidelines a database search was conducted from inception up until 1 May 2017 for peer-reviewed studies on structural or functional neuroimaging assessment of chronic hepatitis C patients without cirrhosis or encephalopathy, with control group. Meta-analyses were performed when possible. RESULTS The final sample comprised 25 studies (magnetic resonance spectroscopy [N = 12], perfusion weighted imaging [N = 1], positron emission tomography [N = 3], single-photon emission computed tomography [N = 4], functional connectivity in resting state [N = 1], diffusion tensor imaging [N = 2] and structural magnetic resonance imaging [N = 2]). The whole sample was of 509 chronic hepatitis C patients, with an average age of 41.5 years old and mild liver disease. A meta-analysis of magnetic resonance spectroscopy studies showed increased levels of choline/creatine ratio (mean difference [MD] 0.12, 95% confidence interval [CI] 0.06-0.18), creatine (MD 0.85, 95% CI 0.42-1.27) and glutamate plus glutamine (MD 1.67, 95% CI 0.39-2.96) in basal ganglia and increased levels of choline/creatine ratio in centrum semiovale white matter (MD 0.13, 95% CI 0.07-0.19) in chronic hepatitis C patients compared with healthy controls. Photon emission tomography studies meta-analyses did not find significant differences in PK11195 binding potential in cortical and subcortical regions of chronic hepatitis C patients compared with controls. Correlations were observed between various neuroimaging alterations and neurocognitive impairment, fatigue and depressive symptoms in some studies. CONCLUSIONS Patients with chronic hepatitis C exhibit cerebral metabolite alterations and structural or functional neuroimaging abnormalities, which sustain the hypothesis of hepatitis C virus involvement in brain disturbances.
Collapse
Affiliation(s)
- G Oriolo
- Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigació Biomèdica Arthur Pi I Sunyer (IDIBAPS), Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), University of Barcelona, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - E Egmond
- Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigació Biomèdica Arthur Pi I Sunyer (IDIBAPS), Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), University of Barcelona, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.,Department of Health and Clinical Psychology, Faculty of Psychology, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - Z Mariño
- Liver Unit, Hospital Clinic, IDIBAPS, Centro Investigación Biomédica en Red de Enfermedades hepáticas y digestivas, (CIBEREHD), University of Barcelona, Barcelona, Spain
| | - M Cavero
- Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigació Biomèdica Arthur Pi I Sunyer (IDIBAPS), Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), University of Barcelona, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - R Navines
- Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigació Biomèdica Arthur Pi I Sunyer (IDIBAPS), Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), University of Barcelona, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain
| | - L Zamarrenho
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo (USP), Ribeirão Preto (SP), Brazil
| | - R Solà
- Liver Unit, Parc de Salut Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
| | - J Pujol
- MRI Research Unit, Department of Radiology, Hospital del Mar, CIBERSAM, Barcelona, Spain
| | - N Bargallo
- Center of Diagnostic Image (CDIC), Hospital Clinic, Magnetic Resonance Image Core Facility, IDIBAPS, Barcelona, Spain
| | - X Forns
- Liver Unit, Hospital Clinic, IDIBAPS, Centro Investigación Biomédica en Red de Enfermedades hepáticas y digestivas, (CIBEREHD), University of Barcelona, Barcelona, Spain
| | - R Martin-Santos
- Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigació Biomèdica Arthur Pi I Sunyer (IDIBAPS), Centro Investigación Biomédica en Red de Salud Mental (CIBERSAM), University of Barcelona, Barcelona, Spain.,Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, Spain.,Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo (USP), Ribeirão Preto (SP), Brazil
| |
Collapse
|
10
|
Imaz ML, Oriolo G, Torra M, Soy D, García-Esteve L, Martin-Santos R. Clozapine Use During Pregnancy and Lactation: A Case-Series Report. Front Pharmacol 2018; 9:264. [PMID: 29636684 PMCID: PMC5881137 DOI: 10.3389/fphar.2018.00264] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Accepted: 03/09/2018] [Indexed: 12/16/2022] Open
Abstract
The current prescription of clozapine in psychotic women of reproductive age makes it crucial to understand its pharmacokinetics during pregnancy and lactation as well as its risk profile for neonatal outcome. The aim of this case series was to provide new evidence on the pharmacokinetic features of clozapine that determine its passage through the placenta and amniotic fluid, as well as the neonatal clozapine elimination half-life (t1/2). This case series demonstrates for the first time that clozapine might show partial placental passage similar to other atypical antipsychotics. Clozapine levels decreased during the first few days in nursing infants. The half-life of clozapine in neonates was slightly higher than previously estimated. Clozapine use in pregnancy may be associated with diabetes mellitus, especially if there is a family history of this disease. Although no acute toxicological effects were observed in the intrauterine exposed newborn, close follow-up of pregnancy is recommended. However, these results must be taken with caution being a case series with small sample size
Collapse
Affiliation(s)
- M Luisa Imaz
- Perinatal Psychiatry Program, Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Giovanni Oriolo
- Department of Medicine, University of Barcelona, Barcelona, Spain.,Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Mercè Torra
- Department of Medicine, University of Barcelona, Barcelona, Spain.,Pharmacology and Toxicology Laboratory, Biochemistry and Molecular Genetics Service, Biomedical Diagnostic Center (CBD), Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Dolors Soy
- Division of Medicines, Pharmacy Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - Lluïsa García-Esteve
- Perinatal Psychiatry Program, Department of Psychiatry and Psychology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.,Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Rocio Martin-Santos
- Department of Medicine, University of Barcelona, Barcelona, Spain.,Department of Psychiatry and Psychology, Hospital Clinic, Institut d'Investigacions Biomèdiques Artur Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red en Salud Mental (CIBERSAM), Barcelona, Spain
| |
Collapse
|
11
|
Espinosa-Martínez L, Fortea A, Oriolo G, González-Rodríguez A, Brunet M, Fortuna V, Parellada E. Antipsychotic therapy amongst Cytochrome P450 2D6 poor metabolizers in the clinical practice: A case report. Actas Esp Psiquiatr 2017; 45:248-255. [PMID: 29044450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/01/2017] [Accepted: 09/01/2017] [Indexed: 06/07/2023]
Affiliation(s)
- Laura Espinosa-Martínez
- Departamento de Psiquiatría y Psicología, Instituto de Neurociencias, Hospital Clínic. Barcelona, España
| | - Adriana Fortea
- Departamento de Psiquiatría y Psicología, Instituto de Neurociencias, Hospital Clínic. Barcelona, España
| | - Giovanni Oriolo
- Departamento de Psiquiatría y Psicología, Instituto de Neurociencias, Hospital Clínic. Barcelona, España
| | - Alexandre González-Rodríguez
- Barcelona Clinic Schizophrenia Unit (BCSU), Instituto de Neurociencias, Hospital Clínic de Barcelona, Universidad de Barcelona. Barcelona, España
| | - Mercè Brunet
- Unitat de Farmacologia i Toxicologia. Centre de Diagnòstic Biomèdic, Hospital Clínic. Barcelona, España
| | - Virginia Fortuna
- Unitat de Farmacologia i Toxicologia. Centre de Diagnòstic Biomèdic, Hospital Clínic. Barcelona, España
| | - Eduard Parellada
- Departamento de Psiquiatría y Psicología, Instituto de Neurociencias, Hospital Clínic. Barcelona, España Barcelona Clinic Schizophrenia Unit (BCSU), Instituto de Neurociencias, Hospital Clínic de Barcelona, Universidad de Barcelona. Barcelona, España Institut d’Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS). Barcelona, España Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM). Barcelona, España
| |
Collapse
|
12
|
Oriolo G, Brugués A, Pintor L, Goikolea JM. Lamotrigine induced dress syndrome in bipolar disorder. Actas Esp Psiquiatr 2017; 45:127-136. [PMID: 28594060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Accepted: 05/01/2017] [Indexed: 06/07/2023]
Affiliation(s)
- Giovanni Oriolo
- MD, Departamento de Psiquiatría y Psicología, ICN, Hospital Clínic de Barcelona, España
| | - A Brugués
- MD, Departamento de Dermatología, Hospital Clínic de Barcelona, España
| | - Luis Pintor
- MD, Psiquiatra, PhD, Unidad de Psiquiatría de Enlace y Psicosomática, Departamento de Psiquiatría y Psicología, ICN, Hospital Clínic de Barcelona, España
| | - José M Goikolea
- Psiquiatra, PhD, Unidad de Trastornos Bipolares, Departamento de Psiquiatría y Psicología, ICN, Hospital Clínic de Barcelona, España
| |
Collapse
|
13
|
Fortea González A, Oriolo G, Balcells Oliveró M, Sánchez del Valle R, Castellvi M. Cognitive impairment induced by benzodiazepine use disorder and its reversibility: a case report. Adicciones 2016; 29:61-63. [PMID: 27749978 DOI: 10.20882/adicciones.767] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Letter to the editor.
Collapse
|
14
|
Oriolo G, Quílez A, Pintor L. Diaphragmatic flutter as conversion symptom: a case report of a neurology-psychiatry-interface disorder. Actas Esp Psiquiatr 2016; 44:193-202. [PMID: 27644103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/01/2016] [Accepted: 09/01/2016] [Indexed: 06/06/2023]
Affiliation(s)
- Giovanni Oriolo
- Departamento de Psiquiatría y Psicología, Instituto Clínico de Neurosciencias Hospital Clinic de Barcelona, Spain
| | - Alejandro Quílez
- MD, Neurologo, Departamento de Neurología, Hospital Universitari Arnau de Vilanova, Lleida, Spain
| | - Luis Pintor
- MD, Psiquiatra, PhD, Unidad de Psiquiatría de Enlace y Psicosomática, Departamento de Psiquiatría y Psicología, ICN, Hospital Clínic de Barcelona, Spain
| |
Collapse
|
15
|
Udina M, Navinés R, Egmond E, Oriolo G, Langohr K, Gimenez D, Valdés M, Gómez-Gil E, Grande I, Gratacós M, Kapczinski F, Artigas F, Vieta E, Solà R, Martín-Santos R. Glucocorticoid Receptors, Brain-Derived Neurotrophic Factor, Serotonin and Dopamine Neurotransmission are Associated with Interferon-Induced Depression. Int J Neuropsychopharmacol 2016; 19:pyv135. [PMID: 26721949 PMCID: PMC4851270 DOI: 10.1093/ijnp/pyv135] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Revised: 11/24/2015] [Accepted: 12/11/2015] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The role of inflammation in mood disorders has received increased attention. There is substantial evidence that cytokine therapies, such as interferon alpha (IFN-alpha), can induce depressive symptoms. Indeed, proinflammatory cytokines change brain function in several ways, such as altering neurotransmitters, the glucocorticoid axis, and apoptotic mechanisms. This study aimed to evaluate the impact on mood of initiating IFN-alpha and ribavirin treatment in a cohort of patients with chronic hepatitis C. We investigated clinical, personality, and functional genetic variants associated with cytokine-induced depression. METHODS We recruited 344 Caucasian outpatients with chronic hepatitis C, initiating IFN-alpha and ribavirin therapy. All patients were euthymic at baseline according to DSM-IV-R criteria. Patients were assessed at baseline and 4, 12, 24, and 48 weeks after treatment initiation using the Patient Health Questionnaire (PHQ), the Hospital Anxiety and Depression Scale (HADS), and the Temperament and Character Inventory (TCI). We genotyped several functional polymorphisms of interleukin-28 (IL28B), indoleamine 2,3-dioxygenase (IDO-1), serotonin receptor-1A (HTR1A), catechol-O-methyl transferase (COMT), glucocorticoid receptors (GCR1 and GCR2), brain-derived neurotrophic factor (BDNF), and FK506 binding protein 5 (FKBP5) genes. A survival analysis was performed, and the Cox proportional hazards model was used for the multivariate analysis. RESULTS The cumulative incidence of depression was 0.35 at week 24 and 0.46 at week 48. The genotypic distributions were in Hardy-Weinberg equilibrium. Older age (p = 0.018, hazard ratio [HR] per 5 years = 1.21), presence of depression history (p = 0.0001, HR = 2.38), and subthreshold depressive symptoms at baseline (p = 0.005, HR = 1.13) increased the risk of IFN-induced depression. So too did TCI personality traits, with high scores on fatigability (p = 0.0037, HR = 1.17), impulsiveness (p = 0.0200 HR = 1.14), disorderliness (p = 0.0339, HR = 1.11), and low scores on extravagance (p = 0.0040, HR = 0.85). An interaction between HTR1A and COMT genes was found. Patients carrying the G allele of HTR1A plus the Met substitution of the COMT polymorphism had a greater risk for depression during antiviral treatment (HR = 3.83) than patients with the CC (HTR1A) and Met allele (COMT) genotypes. Patients carrying the HTR1A CC genotype and the COMT Val/Val genotype (HR = 3.25) had a higher risk of depression than patients with the G allele (HTR1A) and the Val/Val genotype. Moreover, functional variants of the GCR1 (GG genotype: p = 0.0436, HR = 1.88) and BDNF genes (Val/Val genotype: p = 0.0453, HR = 0.55) were associated with depression. CONCLUSIONS The results of the study support the theory that IFN-induced depression is associated with a complex pathophysiological background, including serotonergic and dopaminergic neurotransmission as well as glucocorticoid and neurotrophic factors. These findings may help to improve the management of patients on antiviral treatment and broaden our understanding of the pathogenesis of mood disorders.
Collapse
MESH Headings
- Adult
- Antiviral Agents/therapeutic use
- Brain-Derived Neurotrophic Factor/genetics
- Catechol O-Methyltransferase/genetics
- Depression/chemically induced
- Depression/epidemiology
- Depression/genetics
- Depression/immunology
- Female
- Genetic Predisposition to Disease
- Hepatitis C, Chronic/drug therapy
- Hepatitis C, Chronic/epidemiology
- Hepatitis C, Chronic/genetics
- Hepatitis C, Chronic/psychology
- Humans
- Incidence
- Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics
- Interferon-alpha/adverse effects
- Interferon-alpha/therapeutic use
- Interferons
- Interleukins/genetics
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- Prospective Studies
- Receptor, Serotonin, 5-HT1A/genetics
- Receptors, Glucocorticoid/genetics
- Ribavirin/therapeutic use
- Tacrolimus Binding Proteins/genetics
- Treatment Outcome
- White People/genetics
Collapse
Affiliation(s)
- M Udina
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Navinés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Egmond
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - G Oriolo
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - K Langohr
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - D Gimenez
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Valdés
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Gómez-Gil
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - I Grande
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - M Gratacós
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Kapczinski
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - F Artigas
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - E Vieta
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Solà
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| | - R Martín-Santos
- Department of Psychiatry, Hospital Clínic, Institut d'Investigacions Biomèdiques de Barcelona (IDIBAPS), Spain (Drs Udina, Navinés, Egmond, Oriolo, Valdés, Gómez-Gil, Grande, Vieta, and Martín-Santos); Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Barcelona, Spain (Drs Navinés, Grande, Artigas, Vieta, and Martín-Santos); Department of Psychiatry and Clinical Psychobiology, University of Barcelona, Spain (Drs Oriolo, Valdés, Vieta, and Martín-Santos); Liver Section, Parc de Salut Mar, UAB, Barcelona, Spain (Drs Navinés, Gimenez, and Solà); Department of Clinical and Health Psychology, Universitat Autónoma de Barcelona (UAB), Barcelona, Spain (Egmond); Departament d'Estadística, Investigació Operativa, Universitat Politècnica de Catalunya and Research programme in Neurosciences, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain (Dr Langohr); Center of Genomic Regulation, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain (Dr Gratacós); National Institute for Translational Medicine, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil (Dr Kapczinski); Department of Neurochemistry and Neuropharmacology, Institute d'Investigacions Biomèdiques de Barcelona (IBB-CSIC-IDIBAPS), Spain (Dr Artigas)
| |
Collapse
|
16
|
Espinosa L, Fortea A, Oriolo G, Balcells M, Oliveras C. Suicide attempt in alcohol use disorder and Wernicke encephalopathy: A case report. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.2236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
BackgroundThe relation between alcohol dependence and suicidal behavior is well known and alcohol consumption is a risk factor to take in consideration in order to prevent suicidal attempts. Wernicke encephalopathy (WE) is a common acute neurological disorder caused by thiamine deficiency frequently associated with alcohol use disorder and often infra-diagnosed. Just few cases are reported about the possible correlation between suicidal behaviour and Wernicke encephalopathy.ObjectiveTo describe the possible association between suicidal attempts and Wernicke encephalopathy.MethodsWe report the case of a 57 year old man, with past diagnosis of disthymia and amphetamine abuse disorder, and a history of bariatric surgery, who was hospitalized in the intensive care unit (ICU) of hospital clinic for a suicidal attempt by mean of metro railway precipitation. He presented two episodes of psychomotor agitation in the context of an abstinence syndrome that reverted with midazolam continuous perfusion and clonazepam 8 mg per day. Consequently to medical improvement, he was moved to Psychiatry Unit of Addictive Behavior and finally diagnosed with alcohol use disorder.ResultsIn the physical exam, bilateral nystagmus and cerebellar ataxia were observed. Signs of malnutrition were detected in the blood analysis. In a brain magnetic resonance image, volume deficits in the mammillary bodies, thalamus, cortex and corpus callosum, as well as peri-aqueductal altered signal were observed, all signs compatible with Wernicke encephalopathy diagnoses.ConclusionsWernicke encephalopathy is a frequent concomitant condition in patients with alcohol use disorder. The consequent cognitive decline could represent an independent added risk factor for suicidal behavior.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
17
|
Domínguez I, Nuño L, Oriolo G, Quintero R, Navarro V, Gastó C. Clinical status after two-weeks of antidepressant treatment: A prognostic factor in unipolar major depression? Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.1478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Although most unipolar depression clinical guidelines advise against evaluating the efficacy of antidepressant pharmacological treatment until it has been administered in therapeutic doses for a minimum of 4–6 weeks, there is an increasing tendency to make therapeutic decisions after only 2 weeks of treatment. We present a study which aim is to determine whether the clinical course, following 2 weeks of antidepressant treatment, allows therapeutic decisions to be made for patients affected by a moderate/severe depressive episode. The study has an 8-week, prospective, observational design in which all consecutive in- and outpatients with moderate/severe unipolar major depression aged over 17 years received antidepressant treatment based on a standardized treatment protocol. Clinical status was assessed at baseline and at 2-, 4-, and 8-weeks. The final sample consisted of a total of 114 subjects. In our sample, the rate of remitters versus non-remitters was similar between the 2-week improvers and the 2-week non-improvers. It should also be emphasized that it was not possible to explain, based on the epidemiological and clinical characteristics assessed, which 2-week non-improvers would tend towards remission and which would show a partial or full response. Based on these results, for patients affected by a moderate/severe unipolar depressive episode, it would not be appropriate to make new therapeutic decisions following 2 weeks of anti-depressive pharmacological treatment depending on whether the patient has shown clinical improvement or not.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
18
|
Egmond E, Oriolo G, Cavero M, Langohr K, Solà R, Navines R, Martin-Santos R. Substance abuse and quality of life in chronic hepatitis C patients receiving antiviral treatment. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
IntroductionChronic hepatitis C virus (HCV) is one of world's most important chronic infections. HCV can be treated using interferon-alpha (IFNα) and ribavirin (RBV). HCV, IFNα and RBV are known to impair mental and physical life quality. Many HCV-infected individuals have life-prevalence of substance use disorder (SUD).ObjectivesTo study life quality (SF-36) in HCV patients with SUD history during antiviral treatment.MethodsSF-36 questionnaire was assessed in 384 HCV patients at baseline, and at 4, 12, 24, and 48 weeks of treatment. ANCOVA models were used to study the association of SF-36 scores and potential risk factors at baseline. Risk factors from baseline scores over time were studied through linear mixed models, adjusting for baseline scores.ResultsAt baseline, SUD men had worse mental (P = 0.03) and physical health (P = 0.022), and younger patients had worse social functioning (P = 0.011), and mental (P = 0.001) but better physical health (P < 0.001). Figs. 1 and 2 show the results of mental and physical life quality during treatment from baseline.ConclusionsThis study emphasizes the decrease in life quality in HCV patients with SUD before and during antiviral treatment.GrantInstituto de Carlos III-FIS: PSICOCIT-PI110/01827,EU “One way to make Europe”, Ministerio de Economia y Competitividad (MTM2012-38067-C02-01), and support of SGR/2014/1135.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
19
|
Oriolo G, Barbosa L, Imaz ML, Garcia L, Borrego S, Parellada E. Plasma levels of oral risperidone during enteral nutrition in a pregnant schizophrenic patient. Ther Adv Psychopharmacol 2015; 5:133-7. [PMID: 26240750 PMCID: PMC4521445 DOI: 10.1177/2045125314567115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Giovanni Oriolo
- Department of Psychiatry and Psychology, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, Catalonia, Spain
| | - Lucila Barbosa
- Department of Psychiatry, Hospital Provincial del Centenario, Rosário, Argentina
| | - Maria Luisa Imaz
- Perinatal Psychiatric Program, Hospital Clínic de Barcelona, IDIBAPS, Catalonia, Spain
| | - Luisa Garcia
- Perinatal Psychiatric Program, Hospital Clínic de Barcelona, IDIBAPS, Catalonia, Spain
| | - Sergi Borrego
- Department of Neurology, Hospital Clínic de Barcelona, Catalonia, Spain
| | - Eduard Parellada
- Barcelona Clinic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, Universitat de Barcelona, IDIBAPS, CIBERSAM, Catalonia, Spain
| |
Collapse
|
20
|
Abstract
Prior studies have repeatedly reported behavioural benefits to events occurring at attended, compared to unattended, points in time. It has been suggested that, as for spatial orienting, temporal orienting of attention spreads across sensory modalities in a synergistic fashion. However, the consequences of cross-modal temporal orienting of attention remain poorly understood. One challenge is that the passage of time leads to an increase in event predictability throughout a trial, thus making it difficult to interpret possible effects (or lack thereof). Here we used a design that avoids complete temporal predictability to investigate whether attending to a sensory modality (vision or touch) at a point in time confers beneficial access to events in the other, non-attended, sensory modality (touch or vision, respectively). In contrast to previous studies and to what happens with spatial attention, we found that events in one (unattended) modality do not automatically benefit from happening at the time point when another modality is expected. Instead, it seems that attention can be deployed in time with relative independence for different sensory modalities. Based on these findings, we argue that temporal orienting of attention can be cross-modally decoupled in order to flexibly react according to the environmental demands, and that the efficiency of this selective decoupling unfolds in time.
Collapse
Affiliation(s)
- Stefanie Mühlberg
- Departament de Tecnologies de la Informació i les Comunicacions, Universitat Pompeu Fabra, Barcelona, 08018, Spain
| | | | | |
Collapse
|
21
|
|
22
|
Oriolo G, Ulivi G, Vendittelli M. Real-time map building and navigation for autonomous robots in unknown environments. ACTA ACUST UNITED AC 1998; 28:316-33. [DOI: 10.1109/3477.678626] [Citation(s) in RCA: 127] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
23
|
De Luca A, Oriolo G, Samson C. Feedback control of a nonholonomic car-like robot. Lecture Notes in Control and Information Sciences 1998. [DOI: 10.1007/bfb0036073] [Citation(s) in RCA: 234] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
|